SCHEMBL7083217

SCHEMBL7083217

Cc1cnc(C(=O)O)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.50
P4HTM Q9NXG6 7/20 0.50
ASPH Q12797 3/20 0.50
KDM8 Q8N371 2/20 0.50
P4HA1 P13674 1/20 0.50
MIF P14174 1/20 0.50
ALDH1A1 P00352 5/20 0.48
HCAR2 Q8TDS4 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
MAPK1 P28482 1/20 0.46
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28635523 0.98 KDM4E (0.48) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL9318758 0.85 KDM4E (0.60) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL19857491 0.85 GABRP (0.63) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL20161506 0.83 ASPH (0.44) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL12489210 0.83 GABRP (0.47) KDM4EP4HTMASPHKDM8P4HA1
Hydrochloric Acid SCHEMBL23884908 0.83 KDM4E (0.58) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL1759951 0.83 KMO (0.47) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL232024 0.83 KDM4E (0.52) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL935259 0.83 KMO (0.51) KDM4EP4HTMASPHKDM8P4HA1
SCHEMBL1180456 0.83 KDM4E (0.52) KDM4EP4HTMASPHKDM8P4HA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388602-A1 Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections GENASE THERAPEUTICS B V (NL) 2025-12-25 US disclosed
EP-4469461-B1 TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS GENASE THERAPEUTICS B V (NL) 2025-10-15 EP disclosed
EP-4469461-A1 TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS Genase Therapeutics B.V. (NL) 2024-12-04 EP disclosed
CN-118946568-A Tetrahydropyranopyrazole derivatives for the treatment of cancer and viral infections 格纳赛治疗有限公司 2024-11-12 CN disclosed
WO-2023144332-A1 TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS GENASE THERAPEUTICS B.V. (NL) 2023-08-03 WO disclosed
WO-2023144332-A1 TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS GENASE THERAPEUTICS B.V. (NL) 2023-08-03 WO disclosed
WO-2023141511-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2023-07-27 WO disclosed
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
EP-3911652-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS Biogen MA Inc. (US) 2021-11-24 EP disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed
EP-3632899-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RaQualia Pharma Inc. (JP) 2020-04-08 EP disclosed
US-8575200-B2 Pyridin-2-yl derivatives as immunomodulating agents ACTELION PHARMACEUTICALS LTD (CH) 2013-11-05 US disclosed
US-20100331372-A1 PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS VIATRIS ASIA PACIFIC PTE. LTD. (SG) 2010-12-30 US disclosed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331372-A1 PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS IL2, FCGRT, CD4 KDM4E 965/4885P4HTM 1902/4885ASPH 4062/4885
US-20250388602-A1 Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections CCNA1, KRAS, RSU1 KDM4E 4708/4885P4HTM 3016/4885ASPH 2620/4885
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 KDM4E 1768/4885P4HTM 915/4885ASPH 238/4885
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK2, IRAK1 KDM4E 104/4885P4HTM 1811/4885ASPH 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.